Notably, a favorable PSA response was also observed even in patients with a shorter duration to CRPC, which contrasts with the recommendation of the Advanced Prostate Cancer Consensus Conference that DR should be reserved for those whose progression to mCRPC occurs after 36 months. The gene discussed is KLK3; the disease is Familial prostate cancer.